Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has worked diligently but unsuccessfully to produce a single therapy, variously named Pro 140, leronlimab, and Vyrologix.

In development of this particular therapy, CytoDyn has cast its net far and wide both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will actually be being used is actually an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as a combination therapy in the curing of multi-drug-resistant HIV happen to be closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of the last few shares of mine. My 1st CytoDyn article, “CytoDyn: What To Do When It is Too Good In order to Be True?”, set away all of the following prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan offered such an extremely promotional image in the Uptick Newswire employment interview that I came away with an inadequate viewpoint of the business.

Irony of irony, my poor impression of the business has grown steadily, however, the disappointment has not been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger at the moment still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much-storied treatment (which I shall mean as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor of the treatment as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s transaction of $3.5 zillion transfers ownership of the know-how as well as connected intellectual property from Progenics to CytoDyn, and roughly twenty five million mg of bulk drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 million) and the very first brand new drug application approval ($5 million), and even royalty payments of 5 % of net sales upon commercialization.

Since that moment, CytoDyn’s helping nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to purchase a market place cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous therapies and many indications, it has this individual therapy in addition to a “broad pipeline of indications” as it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a likely beneficial therapy of dozens of indications.

The opening banner of its on the website of its (below) shows an active organization with diverse interests albeit focused on leronlimab, multiple illness types, multiple publications and multiple delivering presentations.

Might it all be smoke cigarettes and mirrors? That’s a question I have been asking myself from the really start of the interest of mine in this business. Judging by way of the multiples of a huge number of several commentary on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I am a lot from alone in this question.

CytoDyn is a classic battleground, or perhaps some could say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *